Trial Profile
CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms CORON-ACT
- 12 Oct 2020 Status changed from recruiting to discontinued as it was not possible to recruit the planned number of patients during the planned study period and "Dexamethason" was included in the standard of care for the study population during the courseof the study and inclusion criteria could no longer be met.
- 22 Apr 2020 Status changed from not yet recruiting to recruiting.
- 07 Apr 2020 New trial record